Novo Nordisk moves to strengthen obesity efforts
pharmaphorum
JANUARY 17, 2022
After securing FDA approval for Wegovy last year, Novo Nordisk is strengthening its position in the obesity space through a collaboration with EraCal Therapeutics. Under the joint research plan, the Danish giant will work with EraCal to identify novel drug targets relevant for food intake regulation and additional metabolic phenotypes.
Let's personalize your content